Mark T Osterman1, Faten N Aberra1, Raymond Cross2, Steven Liakos3, Robert McCabe4, Ira Shafran5, Douglas Wolf6, Robert Hardi7, Lisa Nessel8, Colleen Brensinger8, Erin Gilroy8, James D Lewis9. 1. Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. 2. Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland. 3. South Jersey Gastroenterology, Marlton, New Jersey. 4. Minnesota Gastroenterology, Bloomington, Minnesota. 5. Shafran Gastroenterology Center, Winter Park, Florida. 6. Atlanta Gastroenterology Associates, Atlanta, Georgia. 7. Chevy Chase Clinic Research and George Washington University Medical School, Washington, District of Columbia. 8. Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. 9. Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: lewisjd@mail.med.upenn.edu.
Abstract
BACKGROUND & AIMS: Among patients with quiescent ulcerative colitis (UC), lower fecal concentrations of calprotectin are associated with lower rates of relapse. We performed an open-label, randomized controlled trial to investigate whether increasing doses of mesalamine reduce concentrations of fecal calprotectin (FC) in patients with quiescent UC. METHODS: We screened 119 patients with UC in remission on the basis of Simple Clinical Colitis Activity Index scores, FC >50 μg/g, and intake of no more than 3 g/day mesalamine. Participants taking mesalamine formulations other than multimatrix mesalamine were switched to multimatrix mesalamine (2.4 g/day) for 6 weeks; 52 participants were then randomly assigned (1:1) to a group that continued its current dose of mesalamine (controls, n = 26) or a group that increased its dose by 2.4 g/day for 6 weeks (n = 26). The primary outcome was continued remission with FC <50 μg/g. Secondary outcomes were continued remission with FC <100 μg/g or <200 μg/g (among patients with pre-randomization values above these levels). RESULTS: The primary outcome was achieved by 3.8% of controls and 26.9% of the dose escalation group (P = .0496). More patients in the dose escalation group reduced FC to below 100 μg/g (P = .04) and 200 μg/g (P = .005). Among the patients who were still in remission after the randomization phase, clinical relapse occurred sooner in patients with FC >200 μg/g compared with those with FC <200 μg/g (P = .01). CONCLUSIONS: Among patients with quiescent UC and increased levels of FC, increasing the dose of mesalamine by 2.4 g/day reduced fecal concentrations of calprotectin to those associated with lower rates of relapse. Clinicaltrials.gov number: NCT00652145.
RCT Entities:
BACKGROUND & AIMS: Among patients with quiescent ulcerative colitis (UC), lower fecal concentrations of calprotectin are associated with lower rates of relapse. We performed an open-label, randomized controlled trial to investigate whether increasing doses of mesalamine reduce concentrations of fecal calprotectin (FC) in patients with quiescent UC. METHODS: We screened 119 patients with UC in remission on the basis of Simple Clinical Colitis Activity Index scores, FC >50 μg/g, and intake of no more than 3 g/day mesalamine. Participants taking mesalamine formulations other than multimatrix mesalamine were switched to multimatrix mesalamine (2.4 g/day) for 6 weeks; 52 participants were then randomly assigned (1:1) to a group that continued its current dose of mesalamine (controls, n = 26) or a group that increased its dose by 2.4 g/day for 6 weeks (n = 26). The primary outcome was continued remission with FC <50 μg/g. Secondary outcomes were continued remission with FC <100 μg/g or <200 μg/g (among patients with pre-randomization values above these levels). RESULTS: The primary outcome was achieved by 3.8% of controls and 26.9% of the dose escalation group (P = .0496). More patients in the dose escalation group reduced FC to below 100 μg/g (P = .04) and 200 μg/g (P = .005). Among the patients who were still in remission after the randomization phase, clinical relapse occurred sooner in patients with FC >200 μg/g compared with those with FC <200 μg/g (P = .01). CONCLUSIONS: Among patients with quiescent UC and increased levels of FC, increasing the dose of mesalamine by 2.4 g/day reduced fecal concentrations of calprotectin to those associated with lower rates of relapse. Clinicaltrials.gov number: NCT00652145.
Authors: M De Vos; O Dewit; G D'Haens; F Baert; F Fontaine; S Vermeire; D Franchimont; T Moreels; D Staessen; L Terriere; B Vander Cruyssen; E Louis Journal: J Crohns Colitis Date: 2011-12-11 Impact factor: 9.071
Authors: Brian G Feagan; William J Sandborn; Geert D'Haens; Suresh Pola; John W D McDonald; Paul Rutgeerts; Pia Munkholm; Ulrich Mittmann; Debra King; Cindy J Wong; Guangyong Zou; Allan Donner; Lisa M Shackelton; Denise Gilgen; Sigrid Nelson; Margaret K Vandervoort; Marianne Fahmy; Edward V Loftus; Remo Panaccione; Simon P Travis; Gert A Van Assche; Séverine Vermeire; Barrett G Levesque Journal: Gastroenterology Date: 2013-03-22 Impact factor: 22.682
Authors: Michael A Kamm; Gary R Lichtenstein; William J Sandborn; Stefan Schreiber; Kirstin Lees; Karen Barrett; Raymond Joseph Journal: Inflamm Bowel Dis Date: 2009-01 Impact factor: 5.325
Authors: William J Sandborn; Jaroslaw Regula; Brian G Feagan; Elena Belousova; Njegica Jojic; Milan Lukas; Bruce Yacyshyn; Piotr Krzeski; Chyon-Hwa Yeh; Christi A Messer; Stephen B Hanauer Journal: Gastroenterology Date: 2009-09-18 Impact factor: 22.682
Authors: S B Hanauer; W J Sandborn; C Dallaire; A Archambault; B Yacyshyn; C Yeh; N Smith-Hall Journal: Can J Gastroenterol Date: 2007-12 Impact factor: 3.522
Authors: Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne Journal: Gut Date: 2019-09-27 Impact factor: 23.059
Authors: Robert Battat; Parambir S Dulai; Christopher Ma; Vipul Jairath; Brian G Feagan; William J Sandborn; Reena Khanna Journal: Curr Treat Options Gastroenterol Date: 2020-01-04
Authors: Hans H Herfarth; Susan Jackson; Barbara G Schliebe; Christopher Martin; Anastasia Ivanova; Kristen Anton; Robert S Sandler; Millie D Long; Kim L Isaacs; Mark T Osterman; Bruce E Sands; Peter D Higgins; James D Lewis Journal: Inflamm Bowel Dis Date: 2017-01 Impact factor: 5.325